论文部分内容阅读
目的:观察布地奈德(普米克令舒)雾化吸入治疗婴幼儿毛细支气管炎临床疗效。方法:将126例婴幼儿毛细支气管炎患儿随机分为治疗组66例、对照组60例。治疗组应用布地奈德雾化吸入液1mg加入注射用水5ml,氧驱动雾化吸入,2次/d,对照组同时加用静脉应用地塞米松0.25mg.kg-1.d-1,喘定5mg.kg-1.d-1,观察疗效。结果:治疗组与对照组临床显效率分别为48.8%和36.5%,总有效率86.9%和62.8%,两组差异有统计学意义(P<0.05)。结论:联合应用布地奈德氧气驱动雾化吸入治疗婴幼儿毛细支气管炎较单纯静脉用药具有明显优越性,简便易行,基层医院容易操作,值得推广。
Objective: To observe the clinical efficacy of budesonide (pulmicort) aerosol inhalation in the treatment of infantile bronchiolitis. Methods: A total of 126 infants with bronchiolitis were randomly divided into treatment group (66 cases) and control group (60 cases). Treatment group budesonide inhalation solution 1mg injection water 5ml, aerosol inhalation inhalation, 2 times / d, while the control group plus intravenous dexamethasone 0.25mg.kg-1.d-1, asthma 5mg.kg-1.d-1, observe the effect. Results: The clinical effective rates of the treatment group and the control group were 48.8% and 36.5% respectively, with a total effective rate of 86.9% and 62.8%. There was significant difference between the two groups (P <0.05). CONCLUSION: Combined use of budesonide oxygen driven atomization inhalation for the treatment of infantile bronchiolitis has obvious advantages over simple intravenous drug administration. It is simple and easy to operate, and is worthy of promotion.